TELA Bio (NASDAQ:TELA – Get Free Report) had its price objective dropped by stock analysts at JMP Securities from $20.00 to $15.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has a “market outperform” rating on the stock. JMP Securities’ price objective would suggest a potential upside of 224.68% from the company’s previous close.
TELA Bio Stock Performance
NASDAQ:TELA opened at $4.62 on Friday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 5.75 and a current ratio of 6.84. The stock has a market capitalization of $113.14 million, a P/E ratio of -2.24 and a beta of 1.03. The company has a 50 day moving average price of $7.14 and a 200 day moving average price of $8.94. TELA Bio has a fifty-two week low of $4.26 and a fifty-two week high of $13.18.
TELA Bio (NASDAQ:TELA – Get Free Report) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.12. The firm had revenue of $14.49 million during the quarter, compared to analysts’ expectations of $14.60 million. TELA Bio had a negative net margin of 82.43% and a negative return on equity of 228.47%. Equities research analysts forecast that TELA Bio will post -2.15 EPS for the current year.
Hedge Funds Weigh In On TELA Bio
About TELA Bio
TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.
- Five stocks we like better than TELA Bio
- Dividend Capture Strategy: What You Need to Know
- MarketBeat Week in Review – 11/6 – 11/10
- How to Invest in the Entertainment Industry
- Data giants MongoDB and Snowflake just got upgraded
- Best Aerospace Stocks Investing
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.